Compare Hershey Co (HSY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Novo Nordisk A/S — how do they compare? Hershey Co trades at $171.51 (market cap $34.83B), while Novo Nordisk A/S trades at $49.4 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 6.3× Hershey Co's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| HSY | NVO | |
|---|---|---|
Market Cap | $34.83B | $220.53B |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $71.70 |
52-Week Low | $162.31 | $35.29 |
Enterprise Value | $39.63B | $239.49B |
Dividend Yield | 3.38% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $171.72, showing modest daily gains of 0.18%. The stock faces bearish technical signals with recent price action near support at $170, while fundamentals reveal mixed performance with strong earnings beats but compressed margins. Recent Q1 2026 EPS of $2.35 exceeded expectations by 15%, though net income margin declined to 7.55% in 2025 from 19.82% in 2024 due to cocoa cost pressures. The company maintains solid cash flow generation with $2.28B operating cash flow in 2025.
Hershey presents a cautious opportunity as margin recovery begins in Q2 2026, with analyst consensus target of $208.42 offering 21% upside. However, volume concerns and competitive pressures pose near-term risks. The 3.3% dividend yield provides income support while investors await evidence of sustained sales volume recovery and margin expansion in upcoming earnings.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
